Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
Relmada Therapeutics announced it will present two abstracts regarding its lead asset NDV-01 at the American Urology Association annual meeting in May. The presentations will include 12-month Phase 2 data update for high-risk non-muscle invasive bladder cancer and an overview of the Phase 3 registrational program.
Key figures
- Us prevalent cases
- 744000
- Patent protection through
- 2038
- Phase 3 initiation timeline
- mid-2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.